Annovis Bio Inc. will present at Fierce Biotech Week 2026 in Boston, with President and CEO Maria Maccecchini, Ph.D., scheduled to speak on 13 May 2026 from 1:40 PM to 2:05 PM in Picasso 4&5.
The presentation will trace the scientific basis for understanding Alzheimer’s disease as driven by multiple aggregating neurotoxic proteins and examine the historical gap between that evidence and the field’s reliance on a single-protein approach.
Annovis is a Phase 3 clinical-stage biotechnology company developing the investigational once-daily oral therapy buntanetap. The company describes buntanetap as a translational inhibitor that targets multiple proteins, including APP, amyloid beta, tau, alpha-synuclein and TDP-43.
The company claims buntanetap has shown meaningful clinical benefits supported by encouraging biomarker data and is now in a pivotal Phase 3 clinical trial. The presentation will be followed by a Q&A and is open to conference participants.
